| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
438.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
2,447 |
78,990 |
96,836 |
590,364 |
| Total Sell Value |
$19,013 |
$301,730 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
1 |
9 |
14 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-11-05 |
4 |
OE |
$2.73 |
$54,340 |
D/D |
19,282 |
118,800 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-11-04 |
4 |
AS |
$50.41 |
$2,597,140 |
D/D |
(51,519) |
99,518 |
|
84% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-11-04 |
4 |
OE |
$2.73 |
$140,647 |
D/D |
51,519 |
151,037 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-10-16 |
4 |
AS |
$50.25 |
$1,467,212 |
D/D |
(29,199) |
99,518 |
|
84% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-10-16 |
4 |
OE |
$2.73 |
$79,713 |
D/D |
29,199 |
128,717 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-10-01 |
4 |
AS |
$40.26 |
$1,426,065 |
D/D |
(35,000) |
99,518 |
|
152% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-10-01 |
4 |
OE |
$2.73 |
$95,550 |
D/D |
35,000 |
134,518 |
|
- |
|
| Valamehr Bahram |
Chief Development Officer |
• – – |
2020-09-14 |
4 |
AS |
$34.65 |
$907,024 |
D/D |
(25,000) |
87,211 |
|
139% |
|
| Valamehr Bahram |
Chief Development Officer |
• – – |
2020-09-14 |
4 |
OE |
$1.69 |
$68,778 |
D/D |
25,000 |
112,211 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2020-09-14 |
4 |
AS |
$35.40 |
$907,540 |
D/D |
(25,000) |
118,091 |
|
139% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2020-06-11 |
4 |
B |
$28.31 |
$39,999,992 |
I/I |
1,412,928 |
12,629,737 |
2.25 |
60% |
|
| Rastetter William H |
Director |
– • – |
2020-03-30 |
4/A |
GA |
$0.00 |
$0 |
I/I |
28,461 |
146,821 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2020-03-30 |
4/A |
GD |
$0.00 |
$0 |
D/D |
28,461 |
0 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2020-03-30 |
4 |
OE |
$1.37 |
$38,992 |
D/D |
28,461 |
28,461 |
|
- |
|
| Valamehr Bahram |
Chief Development Officer |
• – – |
2020-02-03 |
4 |
OE |
$1.69 |
$1,949 |
D/D |
1,153 |
87,211 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2020-01-30 |
4 |
AS |
$25.45 |
$636,303 |
D/D |
(25,000) |
419,969 |
|
28% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2020-01-30 |
4 |
OE |
$2.70 |
$67,500 |
D/D |
25,000 |
444,969 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2020-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
66,000 |
419,969 |
|
- |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-01-08 |
4 |
S |
$20.72 |
$118,085 |
D/D |
(5,700) |
99,518 |
|
-25% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2020-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
105,218 |
|
- |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2020-01-08 |
4 |
S |
$20.70 |
$117,986 |
D/D |
(5,700) |
143,091 |
|
-25% |
|
| Shoemaker Daniel D |
Chief Scientific Officer |
• – – |
2020-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
148,791 |
|
- |
|
| Valamehr Bahram |
Chief Development Officer |
• – – |
2020-01-08 |
4 |
S |
$20.69 |
$117,947 |
D/D |
(5,700) |
86,058 |
|
-25% |
|
| Valamehr Bahram |
Chief Development Officer |
• – – |
2020-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
91,758 |
|
- |
|
297 Records found
|
|
Page 8 of 12 |
|
|
0.18 (4.64%) 
